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Abstract
Introduction: The purpose of this study was to evaluate and compare the serum levels and local expression of
resistin in patients with idiopathic inflammatory myopathies to controls, and to determine the relationship
between resistin levels, inflammation and disease activity.
Methods: Serum resistin levels were determined in 42 patients with inflammatory myopathies and 27 healthy
controls. The association among resistin levels, inflammation, global disease activity and muscle strength was
examined. The expression of resistin in muscle tissues from patients with inflammatory myopathies and healthy
controls was evaluated. Gene expression and protein release from resistin-stimulated muscle and mononuclear cells
were assessed.
Results: In patients with inflammatory myopathies, the serum levels of resistin were significantly higher than those
observed in controls (8.53 ± 6.84 vs. 4.54 ± 1.08 ng/ml, P < 0.0001) and correlated with C-reactive protein (CRP)
levels (r = 0.328, P = 0.044) and myositis disease activity assessment visual analogue scales (MYOACT) (r = 0.382, P
= 0.026). Stronger association was observed between the levels of serum resistin and CRP levels (r = 0.717, P =
0.037) as well as MYOACT (r = 0.798, P = 0.007), and there was a trend towards correlation between serum resistin
and myoglobin levels (r = 0.650, P = 0.067) in anti-Jo-1 positive patients. Furthermore, in patients with
dermatomyositis, serum resistin levels significantly correlated with MYOACT (r = 0.667, P = 0.001), creatine kinase (r
= 0.739, P = 0.001) and myoglobin levels (r = 0.791, P = 0.0003) and showed a trend towards correlation with CRP
levels (r = 0.447, P = 0.067). Resistin expression in muscle tissue was significantly higher in patients with
inflammatory myopathies compared to controls, and resistin induced the expression of interleukins (IL)-1b and IL-6
and monocyte chemoattractant protein (MCP)-1 in mononuclear cells but not in myocytes.
Conclusions: The results of this study indicate that higher levels of serum resistin are associated with
inflammation, higher global disease activity index and muscle injury in patients with myositis-specific anti-Jo-1
antibody and patients with dermatomyositis. Furthermore, up-regulation of resistin in muscle tissue and resistin-
induced synthesis of pro-inflammatory cytokines in mononuclear cells suggest a potential role for resistin in the
pathogenesis of inflammatory myopathies.
Introduction
The inflammatory myopathies are a group of acquired
skeletal muscle diseases that include polymyositis (PM),
dermatomyositis (DM), inclusion body myositis, and
overlap and cancer-associated myositis. Inflammatory
myopathies are clinically characterised by proximal mus-
cle weakness and skin changes in DM. An autoimmune
origin of inflammatory myopathies is supported by their
association with other autoimmune diseases, the pre-
sence of autoantibodies, the involvement of histocom-
patibility genes, the evidence of T-cell-mediated
myotoxicity or complement-mediated microangiopathy,
and their responses to immunotherapy [1]. Both diseases
are also characterised by mononuclear inflammatory cell
infiltration in skeletal muscle tissue, muscle fibre necro-
sis and regeneration. The inflammatory infiltrates in the
muscle tissue of DM patients primarily include CD4+ T
cells, B cells and dendritic cells in predominantly peri-
mysial distribution, while affected muscle tissue in PM
patients is characterised by endomysial presence of CD8
+ T cells and macrophages, which often surround and
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invade non-necrotic muscle fibres [1]. The pathogenesis
of inflammatory myopathies has not yet been completely
elucidated, but several cytokines and chemokines pro-
duced by immune cells and myocytes have already been
shown to be involved in the process of muscle tissue
damage during myositis [reviewed in [2]].
Resistin, also known as adipocyte-secreted factor
(ADSF) or found in inflammatory zone 3 (FIZZ3), is a
member of the adipokine family. Originally, resistin was
found in adipocytes to induce insulin resistance in mice.
It has been associated with several metabolic disorders
but also with cancer, inflammatory and immune-
mediated diseases [3]. Resistin is up-regulated by inflam-
matory mediators in peripheral blood mononuclear cells
(PBMC) and induces the expression of pro-inflammatory
cytokines, such as interleukin (IL)-6, IL-8, monocyte
chemoattractant protein (MCP)-1 and tumour necrosis
factor (TNF)-a, angiogenic factors and extracellular
matrix metalloproteinases, suggesting a broad contribu-
tion to many pathological conditions [4-11].
Therefore, we assessed the serum resistin level and its
expression in muscle tissues from patients with idio-
pathic inflammatory myopathies and studied the poten-
tial role of resistin in the pathogenesis of muscle tissue
damage.
Materials and methods
Patients characteristics
Our study consisted of 42 patients with inflammatory
myopathies and 27 healthy controls. All patients under-
went muscle biopsy that was guided by positive mag-
netic resonance imaging (MRI) findings from affected
muscles [12]. The specific pattern of muscle biopsy,
including the immunohistological [13,14] and clinical
investigation, showed that 17 patients suffered from DM
and 25 from other types of myositis. Based on the novel
clinicoserological criteria [15], four patients with myosi-
tis could be classified as pure PM, while 21 had overlap
myositis. These patients had at least one clinical overlap
feature and/or an overlap antibody [15].
Patients were recruited from the inpatient and outpa-
tient departments of the Institute of Rheumatology in
Prague. Disease activity was assessed using myositis dis-
ease activity assessment visual analogue scales
(MYOACT) that globally score constitutional, articular,
cardiac, pulmonary, gastrointestinal, cutaneous, muscle
organs or systems [16]. Manual muscle testing of eight
muscle groups (MMT8) was performed and included
one axial, five proximal (two upper extremity, three
lower extremity), and two distal muscles (one upper,
one lower extremity) [17]. Written informed consent
from each participant was obtained prior to enrolment,
and the study was approved by the local ethics
committee.
Laboratory measurements
Peripheral blood was obtained from all patients at the
time of clinical assessment and from healthy donors. A
routine laboratory analysis was performed on fresh
serum of patients with inflammatory myopathies. C-
reactive protein (CRP) levels in patients and healthy
controls were determined by an immuno-turbidimetric
technique using an Olympus biochemical analyser
(model AU 400, Tokyo, Japan). Creatine kinase and
myoglobin levels were measured by routine laboratory
methodology using Olympus analyser. All collected
serum was stored at -80°C until further analysis. Serum
resistin levels were measured with commercially avail-
able ELISA according to the manufacturer’s protocol
(Biovendor, Brno, Czech Republic). The levels of IL-1b,
IL-6, TNFa and MCP-1 (RayBiotech, Norcross, GA,
USA), along with the levels of perforin (Abcam, Cam-
bridge, UK) and granzyme (Abcam) in cell culture
supernatants were measured using commercially avail-
able ELISA kits. The absorbance was measured at 450
nm using an ELISA reader (Tecan Sunrise, Salzburg,
Austria).
Immunohistochemistry
Samples for immunohistochemistry were obtained from
patients with DM (n = 5) and myositis (n = 5) at the
time of diagnostic muscle biopsy. In these patients, the
muscle biopsy was guided by positive magnetic reso-
nance imaging (MRI) findings from affected muscle as
previously described [12]. Muscle tissue samples from
patients with myasthenia gravis (MG, n = 5) were used
as non-inflammatory controls. Muscle tissues were snap
frozen in isopentane (2-ethylbutane, Sigma-Aldrich, St.
Louis, MO, USA) cooled in liquid nitrogen. For the pur-
poses of immunohistochemistry, 5-μm frozen sections
were fixed in acetone and 4% paraformaldehyde and
blocked with 0.3% H2O2. The sections were incubated
in tris buffered saline (TBS) buffer and incubated with a
monoclonal anti-resistin antibody (Phoenix Pharmaceu-
ticals, Inc., Burlingame, CA, USA) at a dilution 1:500 for
one hour. Afterwards, the slides were rinsed again in
TBS buffer. Antigen-antibody complexes were visualised
with a Histofine detection system (Nichirei Biosciences
Inc., Tokyo, Japan) using 3, 3’diaminobensidine as a
chromogene. Rabbit IgG (Dako Cytomation, Glostrup,
Denmark), diluted 1:1,000, was used as a negative con-
trol. The sections were slightly counterstained with Har-
ris’ hematoxylin. All sections were analysed
semiquantitatively by two experienced pathologists who
were blinded to the clinical data. The intensity of resis-
tin expression was scored on a four-point scale (0 to 3).
A staining intensity of 0 represented a negative result,
and scores of 1 to 3 represented weak, moderate and
strong positive staining intensity, respectively.
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Cell culture and stimulation assays
Human skeletal muscle cells (Lonza, Basel, Switzerland)
were cultured at a density of 100,000 cells in a six-well
plate in 2 ml DMEM (Gibco, Carlsbad, CA, USA).
PBMC were isolated by standard Ficoll density gradient
centrifugation from blood samples donated by healthy
donors. Freshly isolated PBMC were resuspended at a
density of 106 cells per well in a 12-well plate in 2 ml of
RPMI 1640 (Gibco, Carlsbad, CA, USA). Both myocytes
and PBMC were stimulated with human recombinant
resistin (Biovendor, Modrice, Czech Republic) at a con-
centration of 10, 100 or 1,000 ng/ml for 6 and 48 hours
at 37°C in 5% CO2 humidified atmosphere. In the initial
experiment, PBMC were stimulated with either resistin
(1,000 ng/μl) alone or in combination with polymyxin B
sulphate (5 ug/ml, Sigma-Aldrich, St. Louis, MO, USA)
to exclude possible endotoxin contamination. For the
gene expression analysis, cells were lysed in RLT buffer
(Qiagen, Hilden, Germany) 6 h after stimulation. The
supernatants were collected following 48 h of stimula-
tion. The samples were stored at -80°C until use.
RNA isolation and TaqMan Real-Time PCR
Total RNA was isolated using a MagNA Pure Compact
RNA Isolation Kit for the MagNA Pure Compact Instru-
ment (Roche Diagnostics, Mannheim, Germany), and
reverse transcription was performed with a High Capa-
city cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA, USA). Real-time PCR was
performed using gene expression assays (Applied Biosys-
tems), and the reaction was performed using a 7900HT
Fast Real-Time PCR System (Applied Biosystems). Data
were analysed using the ddCt method for relative quan-
tification, and 18S was used as an endogenous control.
MTT assay
The evaluation of the proliferation of myocytes after 72
h stimulation with resistin (10, 100, 1,000 ng/ml) was
carried out with an MTT test using dimethylthiazol
diphenyl tetrazolium bromide (Sigma-Aldrich). The
absorbance was measured at 570 nm via ELISA reader
(Tecan Sunrise, Salzburg, Austria).
Statistical analysis
Data are expressed as the mean ± SD or mean ± SEM
where indicated. The Mann-Whitney U test was used
for comparisons between two variables, and the Krus-
kal-Wallis test, along with Dunn’s multiple comparison
tests, was used for comparisons among more than two
variables. Paired T-tests were used for statistical analyses
of gene expression. Spearman’s and Pearson correlation
coefficients were used to correlate any two variables
with non-normal and normal distribution, respectively.
P-values less than 0.05 were considered statistically
significant. The analysis and the graphs were performed
using GraphPad Prism 5 (version 5.02; GraphPad Soft-
ware, La Jolla, CA, USA).
Results
Characteristics of patients
The characteristics of patients and healthy controls
included in this study are given in Table 1. Our study
group included 17 muscle biopsy-verified patients with
DM and 25 with other types of myositis. Out of these,
four had pure PM while 21 fulfilled criteria for overlap
myositis. The mean duration of myopathy symptoms
ranged from 1 to 154 months. Proximal muscle weak-
ness occurred in 95% of patients. Rash was present in
40%, heliotrope rash in 30%, Gottron’s papules/signs in
28%, V sign rash in 28%, shawl sign in 14% and
mechanics hands in 35% of patients. The Raynaud
Table 1 Characteristics of patients with idiopathic
inflammatory myopathies and healthy controls
Characteristic IIM HC
N 42 27
Age (years) 53.8 ± 14.2 49.5 ± 8.6
Sex (F/M) 31/11 22/5
CRP (mg/l) 9.3 ± 21.6 1.8 ± 1.5
CK (ukat/l, ULN 2.7) 33.6 ± 58.2 NA
Myoglobin (μg/l, ULN 70) 1345 ± 2422 NA
Clinical activity of myositis
MYOACT global 0.15 ± 0.11 NA
MMT8 (maximum 80) 65.34 ± 12.31 NA
Autoantibodies (%)
Anti-Jo-1 24 NA
Anti-Ro-52 37 NA
Anti-Ro-60 2 NA
Anti-PL-7 5 NA
Anti-PM-Scl-100 12 NA
Anti-PM-Scl-75 7 NA
Anti-Mi-2 12 NA
Anti-Ku 2 NA
Anti-SRP 5 NA
Anti-U1RNP 5 NA
Anti-histones 5 NA
Other (AMA, M2, CENP-B) 2 NA
Negative 21 NA
Treatment (%)
Before therapy 19 0
Treatment less than 1 month 53 0
Treatment more than 1 month 26 0
Glucocorticoids 67 0
Others 19 0
Abbreviations: CK, creatine kinase; CRP, C-reactive protein; F, female; HC,
healthy controls; IIM, inflammatory myopathies; M, male; MMT8, manual
muscle testing of eight muscle groups; MYOACT, disease activity assessment
visual analogue scales; N, number; NA, not analysed
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phenomenon was present in 21% of patients, arthritis in
26% and dysphagia in 49%. Myositis-associated intersti-
tial lung disease and cardiac involvement was diagnosed
in 44% and 23% of patients with inflammatory myopa-
thies. Eight patients were assessed prior to treatment
initiation, and 23 patients were treated for less than one
month. All other patients underwent treatment for more
than one month. In the 29 patients treated with gluco-
corticoids, the median dose was 40 mg of prednisone or
its equivalent/day ranging from 7.5 to 85 mg/day. Seven
patients received methotrexate, one patient received
methotrexate in combination with cyclosporine A and
one patient was treated with azathioprine.
Increased resistin levels and disease activity in patients
with inflammatory myopathies
The serum resistin levels were significantly higher in
patients with inflammatory myopathies than in healthy
controls (8.53 ± 6.84 ng/ml vs. 4.54 ± 1.08 ng/ml, P <
0.0001, Figure 1). Patients with both DM (7.39 ± 3.75
ng/ml, P < 0.01) and overlap myositis (9.65 ± 8.88 ng/
ml, P < 0.001) had significantly higher levels of resistin
compared to healthy controls. There were no significant
differences in the levels of serum resistin between
patients with DM and other types of myositis (7.39 ±
3.75 vs. 9.31 ± 8.30 ng/ml, P = 0.626) or between anti-
Jo-1 positive and anti-Jo-1 negative patients (9.459 ±
5.948 vs. 8.242 ± 7.153, P = 0.281). The serum levels of
resistin were comparable between male and female
patients (7.160 ± 3.363 vs. 7.864 ± 4.459, P = 0.761) and
were not affected by age (r = -0.154, P = 0.331) or dis-
ease duration (r = -0.104, P = 0.513). Furthermore,
resistin serum levels did not differ significantly between
patients treated with glucocorticoids for less and more
than one month, and treatment with other immunosup-
pressive agents also did not affect the serum resistin
levels. The resistin levels were not significantly different
between patients with and without arthritis or patients
with and without interstitial lung disease although these
compartments may be a potential source of resistin.
In patients with inflammatory myopathies, but not in
healthy controls, the serum resistin levels correlated
with the CRP levels (r = 0.328, P = 0.040) and, interest-
ingly, positively correlated with the global MYOACT
score (r = 0.382, P = 0.026). In contrast, resistin levels
correlated neither with the creatine kinase and myoglo-
bin levels nor with the MMT8 score in patients with
inflammatory myopathies. Furthermore, we found that
resistin serum levels significantly correlated with CRP
levels (r = 0.717, P = 0.037) and MYOACT (r = 0.798, P
= 0.007) in anti-Jo-1 positive patients, but not in anti-
Jo-1 negative patients (CRP r = 0.140, P = 0.469;
MYOACT r = 0.283, P = 0.181). In addition, there was
a trend towards correlation between serum resistin
levels and myoglobin (r = 0.650, P = 0.067) in anti-Jo-1
positive patients.
In patients with overlap myositis, resistin serum levels
correlated with CRP (r = 0.511, P = 0.030), but not with
other measures. In patients with DM, serum resistin
levels significantly correlated with MYOACT score (r =
0.667, P = 0.001), creatine kinase (r = 0.739, P = 0.001)
and myoglobin levels (r = 0.791, P = 0.0003) and
showed a trend towards correlation with CRP levels (r =
0.447, P = 0.067). Correlations between the levels of
Figure 1 Increased serum resistin levels in patients with idiopathic inflammatory myopathies (IIM) compared with healthy controls
(HC).
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serum resistin and parameters of clinical myositis activ-
ity are summarized in Table 2.
Expression of resistin in muscle tissue
The assessment of resistin staining intensity in inflam-
matory infiltrates of the sections from muscle biopsies
revealed a mean intensity of 1.8 in myositis and 1.6 in
DM patients on the 0 to 3 scale. As expected, no lym-
phocytes were present in control individuals with MG.
Therefore, muscle tissue samples from MG patients
were used as non-inflammatory controls. We found that
resistin expression in muscle tissues from patients with
inflammatory myopathies was significantly higher when
compared with control muscle tissues from patients
with MG (Figure 2). The increased expression of resistin
was particularly localised in scattered mononuclear cells
and in mononuclear cells in inflammatory infiltrates sur-
rounding large vessels and muscle fibres in patients with
inflammatory myopathies. Mild resistin expression was
observed in the cytoplasm of some muscle fibres. Resis-
tin staining was observed in regenerating muscle fibres
in four-fifths of myositis and three-fifths of DM patients,
but not in control patients with MG (Figure 2). Identifi-
cation of regenerating muscle fibers was based upon
hematoxylin and eosin staining. Regenerating muscle
fibers were smaller and splitting, with centrally located
vesicular myonuclei. The cytoplasm of regenerating
muscle fibers appeared basophilic.
Effects of resistin on mononuclear cells
PBMC (n = 8) were stimulated with increasing concen-
trations of resistin (0, 10, 100, 1,000 ng/ml) for 6 or 48
h. As shown in Figure 3, treatment of PBMC with resis-
tin resulted in a significant and dose-dependent
induction of IL-1b (up to 6.5-fold), IL-6 (up to 203-fold)
and MCP-1 (up to 10.8-fold). The induction of TNFa at
the mRNA level was only mild (up to two-fold). This
expression pattern was followed by the increased cyto-
kine release into the cell culture supernatants (Figure
4a-d). Cytokine levels after stimulation with the lowest
doses of resistin were comparable with those of unsti-
mulated cells but these values were significantly differ-
ent after stimulation with higher doses of resistin. To
study the effect of resistin on the cytotoxic activity of
PBMC, the perforin and granzyme levels were analysed
in cell culture supernatants. Only the highest concentra-
tions of resistin resulted in a reduction in the release of
both perforin and granzyme (Figure 4e, f).
To exclude endotoxin contamination of human
recombinant resistin, PBMC (n = 3) were stimulated
with resistin (1,000 ng/ml) alone or in combination with
polymyxin B sulphate (5 μg/ml) for 6 h. There were no
differences in the expression of the abovementioned
cytokines, indicating that there was no nonspecific effect
mediated by recombinant resistin (data not shown).
Effects of resistin on myocytes
To assess the ability of resistin to induce a possible
inflammatory response in skeletal muscle cells, as it
does in mononuclear cells, myocytes (n = 9) were stimu-
lated with increasing concentrations of resistin (0, 10,
100, 1,000 ng/ml). Although the treatment of myocytes
with resistin for 6 hours contributed to the slightly
increased gene expression of some pro-inflammatory
cytokines (Figure 3), the release of these cytokines into
the cell culture supernatants after 48 hours from stimu-
lated and unstimulated cells did not significantly differ.
There was also no resistin-associated effect of on the
expression of several type I interferon induced genes,
such as CXCL10, IFI27, IFI44, IFI44L, RSAD2, OAS1,
ISG15, IFIT1, MX1 (data not shown). Furthermore, as
assessed by MTT assay, resistin did not affect prolifera-
tion of skeletal muscle cells in vitro.
Discussion
In this study, we report for the first time an association
between increased levels of serum resistin and the dis-
ease activity of patients with inflammatory myopathies,
particularly in anti-Jo-1 positive and dermatomyositis
patients. Additionally, we found that the expression of
resistin is up-regulated in muscle tissues of patients
with inflammatory myopathies. Lastly, we found that
resistin may contribute to the increased production of
pro-inflammatory cytokines in mononuclear infiltrates,
thus indirectly participating in muscle tissue pathology.
Although resistin was initially associated with meta-
bolic disorders, increased levels of resistin and its posi-
tive correlation with inflammatory markers and disease
Table 2 Correlations between serum levels of resistin and
disease activity in patients with inflammatory
myopathies.
IIM Myositis DM
Parameter Correlation all Jo-1
+
Jo-
1-
pure overlap
MYOACT r 0.382 0.789 0.283 0.866 0.387 0.667
p 0.026 0.007 0.181 0.33 0.125 0.001
MMT8 r -0.055 -0.179 0.002 -0.400 0.020 -0.439
p 0.765 0.632 0.993 0.750 0.944 0.134
Myoglobin r 0.233 0.650 0.114 0.200 0.079 0.791
p 0.159 0.067 0.490 0.917 0.794 0.0003
CK r 0.145 0.417 0.122 0.200 -0.110 0.739
p 0.385 0.270 0.528 0.917 0.663 0.001
CRP r 0.328 0.717 0.14 -0.800 0.511 0.447
p 0.044 0.037 0.469 0.333 0.030 0.067
Abbreviations: CK, creatine kinase; CRP, C-reactive protein; DM,
dermatomyositis; IIM, inflammatory myopathies; Jo-1, anti-Jo-1 antibody;
MYOACT, disease activity assessment visual analogue scales
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activity have been previously demonstrated in patients
with rheumatoid arthritis (RA) [4,18-20]. In a study by
Almehed and colleagues, serum resistin levels did not
differ between patients with systemic lupus erythemato-
sus (SLE) and healthy controls [21]; whereas in another
study, SLE was independently associated with higher
resistin levels [22]. Moreover, in both studies, the levels
of resistin positively correlated with inflammatory mar-
kers, disease-specific measures and renal dysfunction. In
our study, we observed a strong correlation between
higher levels of serum resistin and CRP and, most
importantly, we observed an association with the global
disease activity assessment of inflammatory myopathy.
Importantly, we found that serum resistin levels were
strongly associated with CRP and global disease activity,
and a trend was also observed towards correlation
between resistin levels and myoglobin in patients with
myositis-specific anti-Jo-1 antibody in contrast to anti-
Jo-1 negative patients. Furthermore, resistin levels signif-
icantly correlated with global disease activity and muscle
enzymes in DM patients. These results are in line with
the abovementioned findings, further supporting an
association between resistin and autoimmune rheumatic
diseases [4,18,22]. On the other hand, serum resistin
levels did not correlate with muscle weakness. Thus, it
could be hypothesized that serum resistin concentration
may reflect global disease activity, including
extramuscular organ involvement, rather than functional
impairment in inflammatory myopathies. However, dis-
ease specific mechanisms can be suggested.
Recently, we demonstrated the increased expression of
resistin in immune cells of RA synovial tissue [19]. In the
present study, we consistently observed the up-regulation
of resistin in the mononuclear cells of inflammatory infil-
trates surrounding vessels and muscle fibres in patients
with inflammatory myopathies. In contrast, there was no
expression of resistin in control non-inflammatory muscle
tissue. Importantly, a majority of samples from DM and
myositis patients showed resistin staining in regenerating
muscle fibres, perhaps implicating a contribution of the
muscle tissue to the inflammatory process or influence of
resistin on regenerating/immature muscle precursors in
the pathogenesis of myositis. The presence of fibre degen-
eration and regeneration is a typical histopathological pic-
ture of inflammatory myositis. Initially, muscle repair is
characterized by inflammation and degeneration of
damaged muscle tissue. It is followed by activation, prolif-
eration and differentiation of myogenic, so-called satellite
cells with subsequent fusion and formation of multinu-
cleated muscle fibres. This process requires a crosstalk
between immune and muscle cells, including secreted fac-
tors [23,24]. In fact, at the moment it is not possible to dis-
tinguish the features of the inflammatory myositis that
promote the injury from those that cause muscle
Figure 2 Expression of resistin in muscle tissue. Expression of resistin in affected skeletal muscle tissue from patients with dermatomyositis
(a) and myositis (b) in contrast with no expression in the muscle tissue of myasthenia gravis (c). Expression of resistin in regenerating muscle
fibres (pointed with arrow) in a patient with dermatomyositis (d). Corresponding tissue sections stained with isotype antibodies (e). Resistin
appears as brown. Nuclei were stained with hematoxylin. Original magnification, ×400 (a-c, e) and ×200 (d).
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regeneration and repair [25]. Accordingly, the role of resis-
tin in the pathology of muscle tissue in myositis is under-
pinned by its association with parameters of disease
activity in the group of patients with myositis associated
autoantibody Jo-1. As we found increased systemic and
local levels of resistin in inflammatory myopathies, we
examined the effect of resistin on muscle and mononuc-
lear cells in vitro. In line with previous reports [8,26], we
found that resistin induces expression and synthesis of
several proinflammatory mediators in mononuclear cells,
thus possibly contributing to muscle tissue pathology. As
demonstrated previously, IL-1, IL-6, MCP-1, as well as
TNFa, are increased in myositis muscle tissues and contri-
bute to disease pathogenesis [27-29]. However, these cyto-
kines may have dual function and may not only contribute
to muscle tissue damage, but also to the regeneration and
healing of the muscle tissue [25,30]. Considering the
ambivalent role of several mediators in inflammatory
myositis, dual functions of resistin may be suggested. In
this regard, we observed a trend towards the reduced
synthesis of the cytotoxic enzymes perforin and granzyme
in resistin-stimulated immune cells.
It has been shown that several Toll-like receptors
(TLRs) are expressed in immune cells but are not pre-
sent in the muscle fibres of patients with inflammatory
myopathies [31]. A recent study demonstrated that a
TLR4 receptor mediates the proinflammatory effects of
resistin in human cells [32]. Therefore, we assume that
the lack of resistin-associated effects on myocytes in our
study may be due to the absence of TLR4 receptors on
the surface of these cells. That being said, resistin did
not modulate the expression of several interferon (IFN)-
a/b induced genes that have been recently observed in
tissue of patients with inflammatory myopathies [33].
Interestingly, immature muscle precursors in myositis
biopsy tissues have been recently demonstrated as an
Figure 3 Effects of resistin on inflammatory response in myocytes and peripheral blood mononuclear cells (PBMC). Expression of IL-1a
(a), IL-6 (b), MCP-1 (c) and TNFa (d) mRNA levels after stimulation with human resistin (10, 100, 1,000 ng/ml) for six hours in myocytes and
PBMC. Data are shown as fold changes compared to unstimulated controls (in graphs represented by control bar, rated as 1). Bars represent the
mean + SEM. P-values less than 0.05 were considered statistically significant; * P < 0.05, ** P < 0.01.
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important source of IFN-b, which was, however,
mediated by TLR-3 activation [34].
Conclusion
We have demonstrated that increased levels in tissue as
well as serum concentration of resistin in patients with
inflammatory myopathies correlate with global disease
activity. In patients with myositis-specific anti-Jo-1 antibody
and, particularly, in dermatomyositis patients, elevated
resistin levels associated with disease activity and muscle
enzymes. We suggest that resistin indirectly participates in
muscle tissue damage by inducing the production of pro-
inflammatory cytokines by mononuclear cells. The exact
role of resistin in muscle tissue regeneration or destruction
in inflammatory myopathies needs further study.
Abbreviations
ADSF: adipocyte-secreted factor; CRP: C-reactive protein; DM:
dermatomyositis; F: female; FIZZ3: inflammatory zone 3; HC: healthy controls;
IFN: interferon; IIM: inflammatory myopathies; IL: interleukin; M: male; MCP-1:
monocyte chemoattractant protein 1; MG: myasthenia gravis; MMT8: manual
muscle testing of eight muscle groups; MRI: magnetic resonance imaging;
MYOACT: myositis disease activity assessment visual analogue scales; NA: not
analysed; PBMC: peripheral blood mononuclear cells; PM: polymyositis; RA:
rheumatoid arthritis; SLE: systemic lupus erythematosus; TBS: tris buffered
saline; TLR: Toll-like receptors; TNF: tumour necrosis factor.
Acknowledgements
This work was supported by MH CR research project NS/10614-3, research
project 262512 and research project 00023728.
Author details
1Institute of Rheumatology, Department of Experimental Rheumatology of
the 1st Faculty of Medicine, Charles University in Prague, Na Slupi 4, Prague
2, 128 50, Czech Republic. 2Department of Pathology and Molecular
Medicine, 2nd Faculty of Medicine, Charles University in Prague, V Úvalu 84,
Prague 5, 150 06, Czech Republic. 3Center of Experimental Rheumatology,
University Hospital Zurich, Gloriastrasse 23, Zurich, CH-8091, Switzerland.
Authors’ contributions
MF performed the majority of the in vitro experiments and the statistical
analysis, in addition to preparing the manuscript. HH performed the
laboratory measurements. KK performed the immunohistochemistry and was
involved in enrolling the patients. LAC and MK contributed to in vitro
Figure 4 Effects of resistin on peripheral blood mononuclear cells (PBMC). Resistin induces the release of IL-1a (a), IL-6 (b), MCP-1 (c) and
TNFa (d) and reduces the release of perforin (e) and granzyme (f) from PBMCs into cell culture media after 48 hours. Bars represent the mean
+ SEM. P-values less than 0.05 were considered statistically significant; * P < 0.05,** P < 0.01, *** P < 0.001.
Filková et al. Arthritis Research & Therapy 2012, 14:R111
http://arthritis-research.com/content/14/3/R111
Page 8 of 9
experiments. LP, HM, JZ and JV were involved in enrolling the patients and
their clinical data. SG and JV assisted in the design of the study. LS was in
charge of the design and conception of the study, helped with the
interpretation of the data and with drafting the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 January 2012 Revised: 28 March 2012
Accepted: 11 May 2012 Published: 11 May 2012
References
1. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003,
362:971-982.
2. De Paepe B, Creus KK, De Bleecker JL: Role of cytokines and chemokines
in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009,
21:610-616.
3. Filková M, Haluzík M, Gay S, Senolt L: The role of resistin as a regulator of
inflammation: Implications for various human pathologies. Clin Immunol
2009, 133:157-170.
4. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an
adipokine with potent proinflammatory properties. J Immunol 2005,
174:5789-5795.
5. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL,
Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP: Innate
immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007,
92:2272-2279.
6. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA: An
inflammatory cascade leading to hyperresistinemia in humans. PLoS Med
2004, 1:e45.
7. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR: Resistin
messenger-RNA expression is increased by proinflammatory cytokines in
vitro. Biochem Biophys Res Commun 2003, 309:286-290.
8. Nagaev I, Bokarewa M, Tarkowski A, Smith U: Human resistin is a systemic
immune-derived proinflammatory cytokine targeting both leukocytes
and adipocytes. PLoS ONE 2006, 1:e31.
9. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C: Adipokine
resistin promotes in vitro angiogenesis of human endothelial cells.
Cardiovasc Res 2006, 70:146-157.
10. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin
promotes endothelial cell activation: further evidence of adipokine-
endothelial interaction. Circulation 2003, 108:736-740.
11. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I,
Utsunomiya K, Nagai R: Direct reciprocal effects of resistin and
adiponectin on vascular endothelial cells: a new insight into
adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun
2004, 314:415-419.
12. Tomasová Studynková J, Charvát F, Jarosová K, Vencovsky J: The role of
MRI in the assessment of polymyositis and dermatomyositis.
Rheumatology (Oxford) 2007, 46:1174-1179.
13. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis.
N Engl J Med 1991, 325:1487-1498.
14. Amato AA, Griggs RC: Unicorns, dragons, polymyositis, and other
mythological beasts. Neurology 2003, 61:288-289.
15. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL:
Novel classification of idiopathic inflammatory myopathies based on
overlap syndrome features and autoantibodies: analysis of 100 French
Canadian patients. Medicine (Baltimore) 2005, 84:231-249.
16. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE,
Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L,
Miller F, International Myositis and Clinical Studies Group (IMACS):
International Myositis and Clinical Studies Group (IMACS). International
consensus outcome measures for patients with idiopathic infl ammatory
myopathies. Development and initial validation of myositis activity and
damage indices in patients with adult onset disease. Rheumatology
(Oxford) 2004, 43:49-54.
17. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K,
Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ,
Bowyer SL, Plotz PH, Miller FW, Hicks JE: Validation of manual muscle
testing and a subset of eight muscles for adult and juvenile idiopathic
inflammatory myopathies. Arthritis Care Res (Hoboken) 2010, 62:465-472.
18. Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J,
Müller-Ladner U, Gay S: Adipocytokines in synovial fluid. JAMA 2003,
290:1709-1710.
19. Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D,
Anderlová K, Müller-Ladner U, Pavelka K, Haluzík M: Resistin in rheumatoid
arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007,
66:458-463.
20. Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H,
Eguchi K: The serum evels of resistin in rheumatoid arthritis patients. Clin
Exp Rheumatol 2006, 24:698-701.
21. Almehed K, d’Elia HF, Bokarewa M, Carlsten H: Role of resistin as a marker
of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008,
10:R15.
22. Baker JF, Morales M, Qatanani M, Cucchiara A, Nackos E, Lazar MA, Teff K,
Von Feldt JM: Resistin levels in lupus and associations with disease-
specific measures, insulin resistance, and coronary calcification. J
Rheumatol 2011, 38:2369-2375.
23. Karalaki M, Fili S, Philippou A, Koutsilieris M: Muscle regeneration: cellular
and molecular events. In Vivo 2009, 23:779-796.
24. Tidball JG, Villalta SA: Regulatory interactions between muscle and the
immune system during muscle regeneration. Am J Physiol Regul Integr
Comp Physiol 2010, 298:R1173-1187.
25. Loell I, Lundberg IE: Can muscle regeneration fail in chronic
inflammation: a weakness in inflammatory myopathies? J Intern Med
2011, 269:243-257.
26. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an
adipokine with potent proinflammatory properties. J Immunol 2005,
174:5789-5795.
27. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H: Local
expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic
inflammatory myopathies. Acta Neuropathol 1999, 97:642-648.
28. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M: Decreased expression
of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in
muscle tissue following corticoid treatment in patients with polymyositis
and dermatomyositis. Arthritis Rheum 2000, 43:336-348.
29. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T,
Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM:
Interleukin-6 and type I interferon-regulated genes and chemokines
mark disease activity in dermatomyositis. Arthritis Rheum 2009,
60:3436-3446.
30. Mackiewicz Z, Hukkanen M, Povilenaite D, Sukura A, Fonseca JE, Virtanen I,
Konttinen YT: Dual effects of caspase-1, interleukin-1 beta, tumour
necrosis factor-alpha and nerve growth factor receptor in inflammatory
myopathies. Clin Exp Rheumatol 2003, 21:41-48.
31. Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, Kim DS, Baek SH, Lee SH,
Lee JH, Kim HY, Kim SI: Expression of TLR2, TLR4, and TLR9 in
dermatomyositis and polymyositis. Clin Rheumatol 2010, 29:273-279.
32. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI: Resistin competes with
lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010,
14:1419-1431.
33. Greenberg SA: Dermatomyositis and type 1 interferons. Curr Rheumatol
Rep 2010, 12:198-203.
34. Tournadre A, Lenief V, Eljaafari A, Miossec P: Immature muscle precursors
are a source of interferon-β in myositis: role of Toll-like receptor 3
activation and contribution to HLA class I up-regulation. Arthritis Rheum
2012, 64:533-541.
doi:10.1186/ar3836
Cite this article as: Filková et al.: Resistin in idiopathic inflammatory
myopathies. Arthritis Research & Therapy 2012 14:R111.
Filková et al. Arthritis Research & Therapy 2012, 14:R111
http://arthritis-research.com/content/14/3/R111
Page 9 of 9
